Clinical Drug Investigation

, Volume 34, Issue 7, pp 449–456 | Cite as

Phase 1 Study of the Effect of Icosapent Ethyl on Warfarin Pharmacokinetic and Anticoagulation Parameters

  • Rene A. Braeckman
  • William G. StirtanEmail author
  • Paresh N. Soni
Original Research Article


Background and Objective

Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester approved to reduce triglyceride levels in patients with severe (≥5.65 mmol/L) hypertriglyceridemia. EPA, the active metabolite of IPE, is mainly metabolized via β-oxidation, and studies suggest that omega-3 fatty acids such as EPA may have antithrombotic effects. The objective of this study was to evaluate the effect of IPE on the pharmacokinetic and anticoagulation pharmacodynamics of warfarin, a substrate of cytochrome P450 2C9-mediated metabolism.


Healthy adults received oral warfarin (25 mg) on day 1, oral IPE (4 g/day) on days 8–35, and co-administration on Day 29. Primary pharmacokinetic end points were area under the concentration-versus-time curve from zero to infinity (AUC0–∞) and maximum plasma concentration (C max) for R- and S-warfarin; pharmacodynamic end points were area under the international normalized ratio (INR) effect-time curve after the warfarin dose (AUCINR) and maximum INR (INRmax).


Twenty-five subjects completed the study. AUC0–∞ and C max ratios of geometric means for both R- and S-warfarin following co-administration of warfarin with versus without IPE were within the 90 % confidence intervals of 0.80–1.25. AUCINR, INRmax, and ratios were also similar.


IPE 4 g/day did not significantly change the single-dose AUC0–∞ or C max of R- and S-warfarin or the anticoagulation pharmacodynamics of warfarin when co-administered as racemic warfarin at 25 mg. Co-administration of these drugs was safe and well tolerated in this study of healthy adult subjects.


Warfarin International Normalize Ratio Ezetimibe Racemic Warfarin International Sensitivity Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was designed and sponsored by Amarin Pharma Inc., Bedminster, NJ, USA. Drs. Braeckman and Soni are former employees of Amarin Pharma Inc., Bedminster, NJ, USA, and were employed by Amarin Pharma Inc. during the planning, execution, and manuscript preparation of this study. Medical writing assistance was provided by Beth Daro-Kaftan, PhD, of Peloton Advantage, LLC, Parsippany, NJ, USA, and funded by Amarin Pharma Inc.


  1. 1.
    Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169:572–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.PubMedCrossRefGoogle Scholar
  3. 3.
    Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2013.Google Scholar
  4. 4.
    Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Arnold C, Konkel A, Fischer R, et al. Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol Rep. 2010;62:536–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011.Google Scholar
  8. 8.
    Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol. 2005;45:127–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99:35C–43C.PubMedCrossRefGoogle Scholar
  10. 10.
    Wachira JK, Larson MK, Harris WS. n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br J Nutr. 2014;111:1652–62.Google Scholar
  11. 11.
    Yates RA, Wong J, Seiberling M, et al. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol. 2001;51:429–35.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Rahimy M, Hallen B, Narang P. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. Arzneimittelforschung. 2002;52:890–5.PubMedGoogle Scholar
  13. 13.
    Almeida L, Falcao A, Vaz-da-Silva M, et al. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Eur J Clin Pharmacol. 2008;64:961–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Zimmerman JJ, Raible DG, Harper DM, et al. Evaluation of a potential tigecycline-warfarin drug interaction. Pharmacotherapy. 2008;28:895–905.PubMedCrossRefGoogle Scholar
  15. 15.
    Walker G, Mandagere A, Dufton C, et al. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharmacol. 2009;67:527–34.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Frey R, Muck W, Kirschbaum N, et al. Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol. 2011;51:1051–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Guidance for industry. Drug interaction studies—study design, data analysis, and implications for dosing and labeling. U.S. Department of Health and Human Services; Food and Drug Administration. Accessed 25 March 2014.
  18. 18.
    Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. Clin Pharmacol Drug Devel. 2013 (Epub ahead of print). doi: 10.1002/cpdd.84/abstract.
  19. 19.
    Agren JJ, Vaisanen S, Hanninen O, et al. Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids. 1997;57:419–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Kaminski WE, Jendraschak E, Kiefl R, et al. Dietary omega-3 fatty acids lower levels of platelet-derived growth factor mRNA in human mononuclear cells. Blood. 1993;81:1871–9.PubMedGoogle Scholar
  21. 21.
    Thorwest M, Balling E, Kristensen SD, et al. Dietary fish oil reduces microvascular thrombosis in a porcine experimental model. Thromb Res. 2000;99:203–8.PubMedCrossRefGoogle Scholar
  22. 22.
    von Schacky C, Baumann K, Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids. 2001;36(Suppl):S99–102.CrossRefGoogle Scholar
  23. 23.
    Schmitz PG, McCloud LK, Reikes ST, et al. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol. 2002;13:184–90.PubMedCrossRefGoogle Scholar
  24. 24.
    Eritsland J, Arnesen H, Gronseth K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol. 1996;77:31–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Carroll DN, Roth MT. Evidence for the cardioprotective effects of omega-3 Fatty acids. Ann Pharmacother. 2002;36:1950–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr. 1997;65:1687S–98S.PubMedGoogle Scholar
  27. 27.
    Eritsland J, Arnesen H, Seljeflot I, et al. Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagul Fibrinolysis. 1995;6:17–22.PubMedCrossRefGoogle Scholar
  28. 28.
    Bender NK, Kraynak MA, Chiquette E, et al. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis. 1998;5:257–61.PubMedCrossRefGoogle Scholar
  29. 29.
    Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol. 2007;99:44C–6C.PubMedCrossRefGoogle Scholar
  30. 30.
    Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Rene A. Braeckman
    • 1
  • William G. Stirtan
    • 1
    Email author
  • Paresh N. Soni
    • 1
  1. 1.Amarin Pharma Inc.BedminsterUSA

Personalised recommendations